SAMUEL J. BRODSKY, M.D.; SALLY S. CUTLER, B.S.; DONALD A. WEINER, M.D.; MICHAEL D. KLEIN, M.D.
Verapamil hydrochloride (Isoptin; Knoll Pharmaceuticals, Whippany, New Jersey), a papaverine derivative currently being tested experimentally in the United States, is a calcium channel blocking agent used for treatment of angina pectoris (1, 2), supraventricular arrhythmias (3, 4), and subaortic stenosis (5). Reported adverse effects from verapamil include: hypotension (4, 6), negative inotroppy (6), atrioventricular block (7), and mild nausea and constipation (1). We describe a case of verapamil induced hepatotoxicity.
A 55-year-old white man with Class II exertional angina consented to a double-blind serial treadmill exercise test protocol to evaluate the anti-anginal efficacy of verapamil. Prior cardiac catheterization showed a
BRODSKY SJ, CUTLER SS, WEINER DA, KLEIN MD. Hepatotoxicity Due to Treatment With Verapamil. Ann Intern Med. ;94:490–491. doi: 10.7326/0003-4819-94-4-490
Download citation file:
Published: Ann Intern Med. 1981;94(4_Part_1):490-491.
Cardiology, Coronary Risk Factors, Emergency Medicine, Gastroenterology/Hepatology, HIV.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use